Systems Biology Opens New Research Pathways
Systems Biologists Are Attacking the Encrypted Messages That Would Allow Us to Predict and Change the Course of Disease
Individual Tumor Profiling
Has Tumor Molecular Profiling Enabled More Effective and Less Toxic Cancer Treatment?
Top 10 Under 40
Up-and-Coming Stars Shine in Biopharma Research and Business
Podcast: FDA’s New Commissioner Hits the Ground Running
Scott Gottlieb, M.D., Commits to Speeding Up Drug Reviews, and Maintaining Safety and Efficacy
Few to no drugs have emerged that impact either the cause or progression of diseases of the central nervous system. Early- and late-stage drug failures, mostly with small molecule drugs and the odd peptide, populate the neurodegenerative disease landscape. Companies have moved away from these types of drugs toward biologics like mAb therapeutics. Those that can successfully develop novel treatments, despite the formidable obstacles to drug development, have a lot to gain. The global market for neurodegenerative treatments will exceed $43.4 billion by 2015, Global Industry Analysts predict. Do you think there will be a breakthrough with mAbs?